Recombinant activated human
factor VII (rhFVIIa) is an established
hemostatic agent in
hemophilia, but its mechanism of action remains unclear. Although
tissue factor (TF) is its natural receptor, rhFVIIa also interacts with the
endothelial protein C receptor (
EPCR) through its γ-carboxyglutamic
acid (Gla) domain, with unknown
hemostatic consequences in vivo. Here, we study whether
EPCR facilitates rhFVIIa hemostasis in
hemophilia using a mouse model system. Mouse activated FVII (mFVIIa) is functionally homologous to rhFVIIa, but binds poorly to mouse
EPCR (mEPCR). We modified mFVIIa to gain mEPCR binding using 3
amino acid changes in its Gla domain (L4F/L8M/W9R). The resulting molecule mFVIIa-FMR specifically bound mEPCR in vitro and in vivo and was identical to mFVIIa with respect to TF affinity and procoagulant functions. In macrovascular injury models, hemophilic mice administered mFVIIa-FMR exhibited superior
hemostatic activity compared with mFVIIa. This was abolished by blocking mEPCR and was absent in ex vivo whole blood coagulation assays, implicating a specific mFVIIa-FMR and endothelial mEPCR interaction. Because mFVIIa-FMR models the TF-dependent and
EPCR binding properties of rhFVIIa, our data unmask a novel contribution of
EPCR on the action of rhFVIIa administration in
hemophilia, prompting the rational design of improved and safer rhFVIIa
therapeutics.